Skip to main content

Table 3 Univariate analysis via Cox- regression model of the influence of clinicopathologic variables on survival outcomes in patients with EGFR mutation receiving EGFR-TKIs

From: Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study

variable category PFS OS
HR (95% CI) p-value HR (95% CI) p-value
Smoking history ever-smokers vs. never smoker 1.9(1.31–2.76) 0.001 2.206(1.43–3.40) < 0.001
Smoking dosage never smoker (PY = 0, Ref.) 1   1  
0 < PY ≤10 0.84(0.45–1.55) 0.08 0.96(0.41–2.25) 0.93
11~ 30 PY 2.95(1.76–4.94) < 0.001 2.29(1.29–4.05) 0.004
>  30 PY 8.33(4.18–16.75) < 0.001 4.91(2.66–9.06) < 0.001
11~ 30 PY vs. > 30 PY 2.97(1.35–6.56) 0.007 2.22(1.08–4.57) 0.03
Age > 60 vs. ≤ 60 years 1.05(0.72–1.53) 0.78 0.99(0.64–1.53) 0.98
Sex Male vs. female 1.39(0.78–1.62) 0.084 1.91(1.238–2.947) 0.003
ECOG PS ≥ 2 vs 0–1 1.76(0.99–3.12) 0.05 3.12(1.73–5.62) < 0.001
Stage IV vs. recurrent or III 1.23(1.03–1.46) 0.02 1.4(1.1–1.9) 0.02
Type of EGFR mutation 19 del vs. 21 L858R 1.2(0.81–1.7) 0.36 0.66(0.38–1.15) 0.15
Brain metastasis   1.9(1.3–2.9) 0.001 2.54(1.46–4.41) 0.001
Line of targeted therapy ≥2nd line vs. 1st 1.15(0.80–1.64) 0.439 1.92(1.25–2.93) < 0.001
Histopathology High vs. low to moderate grade adenocarcinoma 1.17(0.81–1.69) 0.39 0.91(0.51–1.65) 0.78
Type of EGFR-TKI   0.95(0.75–1.18) 0.63 1.2 (0.53–2.69) 0.66
  1. Abbreviation: HR hazard ratio, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status
  2. EGFR epidermal growth factor receptor
  3. Hazard ratios and p values are adjusted for patients’ age (≥60 years vs. < 60 years), sex (female vs. male), ECOG status (PS status 0–1 vs. PS status 2–4), initial tumor stage (stage IV vs. III or recurrent), and line of EGFR-TKI (≥2nd vs. 1st line [Ref.]) in Cox-proportional hazard model